Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 28 October 2016, 14 May 2017, 6 June 2017, 19 September 2017, 1 November 2018, 4 December 2018 and 4 April 2019. The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that new data from 17 patients studied at each of Shanghai Ruijin Hospital, Shanghai Changzheng Hospital, and Jiangsu Province People's Hospital involved in the Phase 1/2 LEGEND-2 open-label study (the "**LEGEND-2 Study**") just published in the Proceedings of the National Academy of Sciences of the United States of America. The data showed that treatment with the investigational anti-B-cell maturation antigen ("**BCMA**") chimeric antigen receptor T-cell (CAR-T) therapy LCAR-B38M resulted in deep and durable responses, with a manageable and tolerable safety profile, in patients with advanced relapsed or refractory ("**R/R**") multiple myeloma.

A total of 74 patients were enrolled in the LEGEND-2 Study. Data from the first 11 patients enrolled at the aforesaid hospitals were presented at the 2017 American Society of Hematology ("**ASH**") annual meeting. Results from 57 patients enrolled at the fourth site, The Second Affiliated Hospital of Xi'an Jiaotong University, were previously published in the Journal of Hematology & Oncology and presented at the 2018 ASH annual meeting.

Patients in the LEGEND-2 Study received LCAR-B38M intravenously after lymphodepleting chemotherapy. As of 20 October, 2018, of the 17 evaluable patients, the overall response rate was 88.2%, with 13 patients achieving stringent complete response ("**sCR**"), two achieving very good partial response ("**VGPR**"), and one non-responder. At median follow-up of 14 months, eight patients (47.1%) remained in sCR or VGPR. The progression-free survival was 82.4% at six months and 52.9% at 12 months, and the 12-month overall survival was 82.3%. Adverse events included cytokine release syndrome ("**CRS**") (100%), cytopenia (82.4%), infections (52.9%), and Grade 2 or 3 liver dysfunction (52.9%). Six patients (35.3%) experienced Grade 3 CRS, and one died due to severe CRS and tumor lysis syndrome.

In China, a Phase 2 confirmatory trial (CARTIFAN-1) registered with the Center for Drug Evaluation (CTR20181007, NCT03758417) is currently enrolling patients to further evaluate LCAR-B38M in patients with advanced R/R multiple myeloma. Globally, (i) Legend Biotech USA Inc., a non-wholly-owned subsidiary of the Company, (ii) Legend Biotech Ireland Limited, a non-wholly-owned subsidiary of the Company and (iii) Janssen Biotech, Inc. are advancing the Phase 1b/2 CARTITUDE-1 trial (NCT03548207) with JNJ-68284528 (the same investigational product identified as LCAR-B38M in China) to evaluate its efficacy and safety in adults with R/R multiple myeloma. The study is currently enrolling patients following U.S. Food and Drug Administration clearance of an Investigational New Drug application as announced in May 2018.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise in caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 16 April 2019

As of the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms.Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purpose only*